etanercept
Last reviewed 01/2018
Etanercept is a fusion protein consisting of a recombinant tumour necrosis factor alpha receptor and the (Fc) constant region of human IgG1.
This molecule is able to bind both TNF-alpha and lymphotoxin (TNF-beta).
It is administered by twice weekly sub-cutaneous injection and is licensed for the treatment of rheumatoid arthritis and polyarticular juvenile idiopathic arthritis where treatment with other DMARDs including Methotrexate have failed.
Check the Summary of Product Characteristics before prescribing this drug.
contra-indications in the use of etanercept
clinical efficacy of etanercept
NICE guidance - etanercept and efalizumab for the treatment of adults with psoriasis